You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

October 5, 2012

Import Challenges for Cosmetic Products

Bangkok Post, Corporate Counsellor Column

By harmonizing the technical regulations governing the cosmetics industry in the ASEAN region over the past few years, the ASEAN Cosmetics Association has been the driving force toward better quality and standards. This harmonization has also helped remove trade barriers under the ASEAN Free Trade Area.

The ASEAN Harmonized Cosmetic Regulatory Scheme (AHCRS) has set out the requirements for cosmetic products for all signatories, including Thailand, since January 1, 2008. Since then, a product manufactured or marketed in any signatory country can enter any other signatory country if it complies with the AHCRS requirements.

By harmonizing their regulations, the ten ASEAN countries, and particularly Thailand, have become an extremely attractive market in which cosmetics distributors can expand their businesses. There are, however, some technical regulations that have not been harmonized as they are subject to national controls, such as the restrictions on importation into Thailand.

Importing for Personal Use

The Thai Food and Drug Administration (FDA) has set forth clear guidelines to differentiate between cosmetic product imports intended for personal use and for sale. If a person brings into Thailand more than six items of the same cosmetic product from another country, the Import and Export Inspector from the Thai FDA at the port will conclude that the person intends to import the products for local sale.

Registration Requirements

When importing products for sale, each ASEAN country requires individual registration with the regulatory authorities where the product will be marketed. In Thailand, the FDA is flexible in allowing either a company or an individual to register as a distributor for a cosmetics business. And there is no limitation on the number of importers of one product, so the same product, with the same name, can be imported by several companies.

The Thai FDA requires that the company or person who intends to place any cosmetic on the market must register as an importer with the FDA, as well as register the product itself after the FDA approves the company’s or individual’s registration.

Using the established registration process, many individuals have tried to register themselves as authorized marketers or importers of a broad range of cosmetic products—even well-known products that are already registered with the FDA. These individuals have all eventually failed, as they are unable to produce the specific documentation the FDA requires for product registration. This includes, for example, the full ingredient listing and percentages of all ingredients contained in the product formula. This is important because this kind of information is extremely confidential and belongs only to the product owner and its authorized marketer.

A letter of authorization from the product owner or manufacturer is also required, especially when a well-known product brand is already registered with the FDA. It appears that some of these individuals lack the knowledge and experience to be importers or authorized marketers in accordance with FDA practice.

The FDA has also become more rigorous in post-marketing steps. FDA officials now regularly conduct random inspections of importers. Thai cosmetic companies are therefore required to prepare the four parts of the product information files, which consist of more detailed product information, in case they are randomly inspected.

Parallel Import

Importing cosmetics products into Thailand also creates some uncertainties with regard to parallel imports. For example, a manufacturer might give exclusive authorization to different distributors to sell its products in Malaysia and Thailand. The Malaysian distributor might then decide that it wishes to export the product to Thailand. In doing so, the Malaysian distributor will be required to carry out the registration process, and the Thai FDA will still be in a position to authorize the registration and import of such cosmetics on the basis that all documents have been provided.

If this happens, the Thai distributor, who had independently reached an agreement with the foreign manufacturer to be the only distributor in Thailand, will no longer be the exclusive distributor. The Thai importer would also not be able to claim trademark infringement against the Malaysian distributor. This is because Thailand recognizes the principle of exhaustion of rights. This principle holds that once a product has legally entered the market somewhere (in this case, in Malaysia), then resale of the product anywhere in the world no longer constitutes trademark infringement.

Faced with this scenario, the only available option is for the foreign manufacturer to claim breach of the contract it signed with the parallel importer (the Malaysian distributor), provided a clause exists that indicates that such distributor will not sell outside its designated territory.

In summary, if an individual wishes to import cosmetics into Thailand, he or she should first check the requirements, and then ensure that if they have a distribution agreement with the foreign manufacturer, sufficient provisions are included to allow them to enforce their rights.

RELATED INSIGHTS​ 

August 29, 2023
Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and
July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart
July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding